Matthew A. Murray

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion”.

NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion

Molecular Cancer Research(2024)10.1158/1541-7786.mcr-23-1003

N/A

0.282DataRank · unranked

5 citations

Karlie N. Lucas, Sateja Paradkar, Joseph Edmonds, Sam Friedman, Matthew A. Murray +12 more

Exploiting Metabolic Defects in Glioma with Nanoparticle-Encapsulated NAMPT Inhibitors

Molecular Cancer Therapeutics(2024)10.1158/1535-7163.mct-24-0012

N/A

0DataRank · unranked

7 citations

Katelyn J. Noronha, Yazhe Wang, Anna P. Friedman, Sateja Paradkar, Hee‐Won Suh +5 more

PARG inhibition induces nuclear aggregation of PARylated PARP1

Structure(2024)10.1016/j.str.2024.09.006

N/A

0DataRank · unranked

4 citations

Julia Purcell, Annie Cui, Samuel R. Friedman, Katelyn J. Noronha, Matthew A. Murray +4 more